Localised prostate cancer: clinical and cost-effectiveness of new and emerging technologies

被引:1
|
作者
Philippou, Yiannis [1 ]
Hadjipavlou, Marios [1 ]
Khan, Shahid [1 ]
Ahmed, Kamran [2 ,3 ]
Rane, Abhay [1 ]
机构
[1] East Surrey Hosp, Dept Urol, Canada Ave, Redhill RH1 5RH, Surrey, England
[2] Kings Coll London, MRC Ctr Transplantat, London, England
[3] Guys Hosp, Dept Urol, London, England
关键词
Localised prostate cancer; radical prostatectomy; radiotherapy; brachytherapy; focal therapy; cost-effectiveness; functional and oncological outcomes;
D O I
10.1177/2051415813519628
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In contrast to pharmacological interventions that undergo rigorous clinical testing, recent technological advances in the treatment of prostate cancer (PCa) have particularly been introduced and driven by economic incentives rather than high-quality clinical evidence. In this review we summarise the clinical and cost-effectiveness of new and emerging technologies for localised PCa. We emphasise particularly on robotic prostatectomy, new developments in radiotherapy, novel technologies in focal therapy such as cryosurgery and high-intensity focused ultrasound (HIFU). Robotic-assisted laparoscopic radical prostatectomy (RALRP) has similar oncologic outcomes to open radical retropubic prostatectomy (RRP); however, patients who undergo RALRP are more likely to have improved short-term potency rates. Intensity-modulated radiotherapy (IMRT) and proton-beam therapy (PBT) have similar oncologic outcomes to external-beam radiotherapy (EBRT). IMRT has exhibited an improved gastrointestinal side effect profile compared to EBRT. PBT is not cost-effective compared to other radiotherapy modalities. Early studies of focal therapies in localised PCa have yielded positive results. Treatment decisions should be driven by cancer risk and patient preference rather than by financial incentives or availability of technology.
引用
收藏
页码:239 / 251
页数:13
相关论文
共 50 条
  • [21] Racial Variation in the Cost-effectiveness of Chemotherapy for Prostate Cancer
    Grabner, Michael
    Onukwugha, Eberechukwu
    Jain, Rahul
    Mullins, C. Daniel
    AMERICAN JOURNAL OF MANAGED CARE, 2011, 17 (05): : E151 - E159
  • [22] COST-EFFECTIVENESS OF PROSTATE-CANCER SCREENING AND TREATMENT
    BILGRAMI, S
    ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) : 1054 - 1055
  • [23] RACIAL VARIATION IN THE COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PROSTATE CANCER
    Grabner, M.
    Onukwugha, E.
    Jain, R.
    Mullins, C. D.
    VALUE IN HEALTH, 2011, 14 (03) : A164 - A164
  • [24] Cost-effectiveness analysis of prostate cancer screening and MRI
    Takahashi, Takeshi
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [25] The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index
    Heijnsdijk, Eveline A. M.
    Denham, Dwight
    de Koning, Harry J.
    VALUE IN HEALTH, 2016, 19 (02) : 153 - 157
  • [26] Cost-effectiveness and lung cancer clinical trials
    Du, W
    Reeves, JH
    Gadgeel, S
    Abrams, J
    Peters, WP
    CANCER, 2003, 98 (07) : 1491 - 1496
  • [27] Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer
    Zemplenyi, A. T.
    Kalo, Z.
    Kovacs, G.
    Farkas, R.
    Beothe, T.
    Banyai, D.
    Sebestyen, Z.
    Endrei, D.
    Boncz, I.
    Mangel, L.
    EUROPEAN JOURNAL OF CANCER CARE, 2018, 27 (01)
  • [28] Cost effectiveness of radical prostatectomy over conservative management for localised prostate cancer
    Emberton, M
    Hrouda, D
    JOURNAL OF UROLOGY, 1998, 159 (05): : 301 - 301
  • [29] Pancreatic cancer: Cost-effectiveness of imaging technologies for assessing resectability
    McMahon, PM
    Halpern, EF
    Fernandez-del Castillo, C
    Clark, JW
    Gazelle, GS
    RADIOLOGY, 2001, 221 (01) : 93 - 106
  • [30] The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
    Nicholson, Amanda
    Mahon, James
    Boland, Angela
    Beale, Sophie
    Dwan, Kerry
    Fleeman, Nigel
    Hockenhull, Juliet
    Dundar, Yenal
    HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (87) : 1 - +